78 related articles for article (PubMed ID: 1612550)
41. Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center.
Koike M; Takei T; Uchida K; Honda K; Moriyama T; Horita S; Ogawa T; Yoshida T; Tsuchiya K; Nitta K
Clin Exp Nephrol; 2008 Aug; 12(4):250-255. PubMed ID: 18286351
[TBL] [Abstract][Full Text] [Related]
42. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy.
Shoji T; Nakanishi I; Suzuki A; Hayashi T; Togawa M; Okada N; Imai E; Hori M; Tsubakihara Y
Am J Kidney Dis; 2000 Feb; 35(2):194-201. PubMed ID: 10676716
[TBL] [Abstract][Full Text] [Related]
43. [Prognostic significance of persistent massive proteinuria in progressive IgA nephropathy--a long-term follow-up study].
Kokubo T; Hiki Y; Tateno S; Kobayashi Y
Nihon Jinzo Gakkai Shi; 1994 Jul; 36(7):823-31. PubMed ID: 8072220
[TBL] [Abstract][Full Text] [Related]
44. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy.
Haramaki R; Tamaki K; Fujisawa M; Ikedo H; Haramaki N; Okuda S
Am J Kidney Dis; 2001 Dec; 38(6):1191-8. PubMed ID: 11728950
[TBL] [Abstract][Full Text] [Related]
45. Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases.
Kobayashi Y; Fujii K; Hiki Y; Tateno S; Kurokawa A; Kamiyama M
Nephron; 1988; 48(1):12-7. PubMed ID: 3340251
[TBL] [Abstract][Full Text] [Related]
46. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study.
Kobayashi Y; Hiki Y; Kokubo T; Horii A; Tateno S
Nephron; 1996; 72(2):237-42. PubMed ID: 8684533
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Ishikura K; Hataya H; Honda M; Nozu K; Iijima K; Shima Y; Yoshikawa N;
Pediatr Nephrol; 2015 Jun; 30(6):961-7. PubMed ID: 25487669
[TBL] [Abstract][Full Text] [Related]
48. Effect of corticosteroid and cyclophosphamide in IgA nephropathy patients with heavy proteinuria and/or moderate-severe pathological changes.
Chen KJ; Cheng CH; Wu MJ; Chen CH; Shu KH
J Chin Med Assoc; 2003 May; 66(5):263-70. PubMed ID: 12908567
[TBL] [Abstract][Full Text] [Related]
49. Corticosteroids in IgA nephropathy: a randomised controlled trial.
Pozzi C; Bolasco PG; Fogazzi GB; Andrulli S; Altieri P; Ponticelli C; Locatelli F
Lancet; 1999 Mar; 353(9156):883-7. PubMed ID: 10093981
[TBL] [Abstract][Full Text] [Related]
50. Effect of steroid pulse therapy on post-transplant immunoglobulin A nephropathy.
Matsukuma Y; Masutani K; Tsuchimoto A; Okabe Y; Nakamura M; Kitazono T; Tsuruya K
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():10-16. PubMed ID: 29968415
[TBL] [Abstract][Full Text] [Related]
51. Steroid therapy reduces mesangial matrix accumulation in advanced IgA nephropathy.
Kuriki M; Asahi K; Asano K; Sakurai K; Eiro M; Suzuki H; Watanabe K; Katoh T; Watanabe T
Nephrol Dial Transplant; 2003 Jul; 18(7):1311-5. PubMed ID: 12808167
[TBL] [Abstract][Full Text] [Related]
52. Epidemiological survey and clinical investigation of pediatric IgA nephropathy.
Shibano T; Takagi N; Maekawa K; Mae H; Hattori M; Takeshima Y; Tanizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):111-7. PubMed ID: 26041644
[TBL] [Abstract][Full Text] [Related]
53. Effect of corticosteroids on renal function in progressive IgA nephropathy--long-term follow-up study.
Kobayashi Y; Hiki Y; Fujii K; Kurokawa A; Kamiyama M; Tateno S
Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1135-42. PubMed ID: 3216556
[No Abstract] [Full Text] [Related]
54. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy.
Katafuchi R; Ikeda K; Mizumasa T; Tanaka H; Ando T; Yanase T; Masutani K; Kubo M; Fujimi S
Am J Kidney Dis; 2003 May; 41(5):972-83. PubMed ID: 12722031
[TBL] [Abstract][Full Text] [Related]
55. The influence of steroid therapy in patients with IgA nephropathy.
Masaki T; Yorioka N; Yamakido M
Nephron; 2000 Oct; 86(2):197-8. PubMed ID: 11014996
[No Abstract] [Full Text] [Related]
56. [A proposed cooperation system between physicians in private practice and hospitals to prevent neglect of poor prognostic cases with mild urinary abnormalities].
Mori K
Nihon Jinzo Gakkai Shi; 2001 May; 43(4):340-6. PubMed ID: 11431902
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-6 localization and the prognosis of IgA nephropathy.
Taniguchi Y; Yorioka N; Kumagai J; Katsutani M; Kuratsune M; Amimoto D; Yamakido M
Nephron; 1999 Jan; 81(1):94-8. PubMed ID: 9884428
[TBL] [Abstract][Full Text] [Related]
58. Cyclosporin treatment of IgA nephropathy: a short term controlled trial.
Lai KN; Lai FM; Li PK; Vallance-Owen J
Br Med J (Clin Res Ed); 1987 Nov; 295(6607):1165-8. PubMed ID: 3120928
[TBL] [Abstract][Full Text] [Related]
59. Concomitant therapy with prednisolone and cyclophosphamide in 17 cases with IgA nephropathy.
Katsumata Y; Hasegawa K; Hoshino K
Nihon Jinzo Gakkai Shi; 1985 Mar; 27(3):295-302. PubMed ID: 4021193
[No Abstract] [Full Text] [Related]
60. Moderately proteinuric IgA nephropathy: prognostic prediction of individual clinical courses and steroid therapy in progressive cases.
Kobayashi Y; Hiki Y; Fujii K; Kurokawa A; Tateno S
Nephron; 1989; 53(3):250-6. PubMed ID: 2797345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
